Advisers to the Food and Drug Administration are meeting to review a gene therapy technique called CRISPR to treat sickle cell disease.

<div class="block">Advisers to the Food and Drug Administration are meeting to review a gene therapy technique called CRISPR to treat sickle cell disease.</div>

Need2Know Headlines

FDA Advisers to Review New Sickle Cell Treatment

And currently the only cure for sickle cell disease is a bone marrow transplant, but that could soon change. This is groundbreaking advisor to the Food and Drug Administration are meeting today to review a gene therapy technique. It's called CRISPR. It's a tool that won its inventors a Nobel Prize in 2020. The FDA advisor will review whether or not more research is needed into possible unintended consequences of the treatment. One of the doctors who shared a Nobel Prize for the technique described it as a landmark moment, Jennifer D of the University of California Berkeley said quote, as a scientist, I think we always hope that our work will affect people in a positive way. And this is one of those moments and quote, the FDA is expected to make a final decision in early December. Sickle cell disease largely affects people of African, Middle Eastern and Indian descent.